The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells
M.G. Bernengo(University of Turin), Maria Teresa Fierro(University of Turin), Mauro Novelli(University of Turin), Arianna De Matteis(University of Turin), N Cappello(University of Milan), Pietro Quaglino(Department of Medical Sciences), F Lisa(University of Turin), Paola Savoia(University of Turin)
Cited by 200
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
|European Journal of Cancer|2017|449